NO20012013L - 5HT1 reseptor agonister og metoclopramid for behandling av migrene - Google Patents

5HT1 reseptor agonister og metoclopramid for behandling av migrene

Info

Publication number
NO20012013L
NO20012013L NO20012013A NO20012013A NO20012013L NO 20012013 L NO20012013 L NO 20012013L NO 20012013 A NO20012013 A NO 20012013A NO 20012013 A NO20012013 A NO 20012013A NO 20012013 L NO20012013 L NO 20012013L
Authority
NO
Norway
Prior art keywords
metoclopramide
migraine
treatment
receptor agonists
mammal
Prior art date
Application number
NO20012013A
Other languages
English (en)
Other versions
NO20012013D0 (no
Inventor
George Harry Sands
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20012013D0 publication Critical patent/NO20012013D0/no
Publication of NO20012013L publication Critical patent/NO20012013L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er beskrevet en fremgangsmåte for behandling av migrene i et pattedyr, inkludert et menneske, ved administrering til pattedyret en 5HTrreseptoragonist og spesielt eletriptan, i kombinasjon med metoklopramid. Det er også beskrevet farmasøytiske sammensetninger inneholdende en farmasøytisk akseptabel bærer, en 51-nVreseptoragonist og metoklopramid.
NO20012013A 1998-10-30 2001-04-24 5HT1 reseptor agonister og metoclopramid for behandling av migrene NO20012013L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10632898P 1998-10-30 1998-10-30
PCT/IB1999/001694 WO2000025778A1 (en) 1998-10-30 1999-10-18 5ht1 receptor agonists and metoclopramide for the treatment of migraine

Publications (2)

Publication Number Publication Date
NO20012013D0 NO20012013D0 (no) 2001-04-24
NO20012013L true NO20012013L (no) 2001-04-24

Family

ID=22310818

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012013A NO20012013L (no) 1998-10-30 2001-04-24 5HT1 reseptor agonister og metoclopramid for behandling av migrene

Country Status (34)

Country Link
US (2) US6255334B1 (no)
EP (1) EP1126840A1 (no)
JP (1) JP2002528497A (no)
KR (1) KR20010089363A (no)
CN (1) CN1325304A (no)
AP (1) AP2001002129A0 (no)
AR (1) AR019246A1 (no)
AU (1) AU5994799A (no)
BG (1) BG105534A (no)
BR (1) BR9914901A (no)
CA (1) CA2348543A1 (no)
CO (1) CO4950530A1 (no)
CZ (1) CZ20011468A3 (no)
EA (1) EA200100284A1 (no)
EE (1) EE200100243A (no)
GT (1) GT199900189A (no)
HK (1) HK1040929A1 (no)
HR (1) HRP20010298A2 (no)
HU (1) HUP0104696A3 (no)
ID (1) ID28291A (no)
IL (1) IL141957A0 (no)
IS (1) IS5898A (no)
MA (1) MA26702A1 (no)
NO (1) NO20012013L (no)
OA (1) OA11669A (no)
PA (1) PA8484801A1 (no)
PE (1) PE20001284A1 (no)
PL (1) PL347541A1 (no)
SK (1) SK5522001A3 (no)
TN (1) TNSN99203A1 (no)
TR (1) TR200101174T2 (no)
TW (1) TW524692B (no)
WO (1) WO2000025778A1 (no)
ZA (1) ZA200103322B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
NZ529417A (en) * 2001-05-24 2006-11-30 Alexza Pharmaceuticals Inc Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
WO2002094242A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
WO2003041693A1 (en) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
AU2002363947A1 (en) 2001-11-21 2003-07-24 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
EP1503744A1 (en) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
CA2507159A1 (en) 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
JP5833804B2 (ja) * 2005-04-13 2015-12-16 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
WO2007118314A1 (en) * 2006-04-13 2007-10-25 Neuraxon, Inc. 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
EP2220075A4 (en) * 2007-11-16 2012-02-29 Neuraxon Inc INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN
AU2008321353A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
AU2013202680C1 (en) * 2008-04-28 2016-06-23 Zogenix, Inc. Novel formulations for treatment of migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
EP1024833A1 (en) * 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
GB9709739D0 (en) 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation

Also Published As

Publication number Publication date
BG105534A (en) 2001-12-29
US6255334B1 (en) 2001-07-03
TR200101174T2 (tr) 2001-10-22
EA200100284A1 (ru) 2001-10-22
PL347541A1 (en) 2002-04-08
EE200100243A (et) 2002-12-16
US20010020036A1 (en) 2001-09-06
HRP20010298A2 (en) 2002-06-30
IL141957A0 (en) 2002-03-10
ID28291A (id) 2001-05-10
AR019246A1 (es) 2001-12-26
KR20010089363A (ko) 2001-10-06
HK1040929A1 (zh) 2002-06-28
ZA200103322B (en) 2002-06-10
IS5898A (is) 2001-03-16
EP1126840A1 (en) 2001-08-29
PA8484801A1 (es) 2000-09-29
HUP0104696A3 (en) 2003-05-28
WO2000025778A1 (en) 2000-05-11
NO20012013D0 (no) 2001-04-24
OA11669A (en) 2005-01-05
PE20001284A1 (es) 2000-11-22
CO4950530A1 (es) 2000-09-01
MA26702A1 (fr) 2004-12-20
CN1325304A (zh) 2001-12-05
SK5522001A3 (en) 2002-05-09
AU5994799A (en) 2000-05-22
TW524692B (en) 2003-03-21
AP2001002129A0 (en) 2001-06-30
CZ20011468A3 (cs) 2002-04-17
HUP0104696A2 (hu) 2002-05-29
GT199900189A (es) 2001-04-21
BR9914901A (pt) 2001-07-17
JP2002528497A (ja) 2002-09-03
CA2348543A1 (en) 2000-05-11
TNSN99203A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
NO20012013L (no) 5HT1 reseptor agonister og metoclopramid for behandling av migrene
TW200505900A (en) Muscarinic agonists
NO962130L (no) Synergistisk behandling av Parkinsons sykdom
MXPA02011624A (es) Uso de una composicion de celecoxib para alivio rapido del dolor.
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
MY119403A (en) Novel compounds with analgesic effect.
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
MY115662A (en) Novel compounds with analgesic effect
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
EA200101089A1 (ru) Новый способ лечения
DE59511017D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
EA200400302A1 (ru) Способ лечения первичной бессонницы
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
TW200718423A (en) Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and pharmaceutical composition thereof
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
EP1051994A3 (en) 5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine
EP1051993A3 (en) 5HT1 receptor agonists and either a COX-2 inhibitor or NSAID for the treatment of migraine
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
YU60803A (sh) Upotreba antagonista gal3 receptora u lečenju depresije i/ili uznemirenosti i jedinjenja korisna u tim postupcima

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application